Pulmonx Co. (NASDAQ:LUNG) Director Sells $459,150.84 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 55,453 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the sale, the director now owns 1,011,974 shares in the company, valued at $8,379,144.72. The trade was a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pulmonx Stock Performance

Pulmonx stock opened at $9.20 on Thursday. The company has a market cap of $363.09 million, a PE ratio of -6.39 and a beta of 0.64. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $10.48. The company’s 50-day moving average is $6.70 and its two-hundred day moving average is $6.85.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The business had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Equities analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. 272 Capital LP bought a new stake in Pulmonx in the third quarter valued at about $25,000. BNP Paribas Financial Markets bought a new position in Pulmonx during the fourth quarter worth about $43,000. R Squared Ltd acquired a new position in shares of Pulmonx during the 4th quarter worth about $46,000. ProShare Advisors LLC bought a new stake in shares of Pulmonx in the 4th quarter valued at about $72,000. Finally, Stifel Financial Corp acquired a new stake in shares of Pulmonx in the 4th quarter valued at approximately $81,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on LUNG. Stifel Nicolaus reduced their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Citigroup reiterated a “neutral” rating and set a $7.50 target price (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company decreased their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.